A subset of pro-inflammatory CXCL10+ LILRB2+ macrophages derives from recipient monocytes
and drives renal allograft rejection

Alexis Varin[1]‡, Jovanne Palvair[1]‡, Lennie Messager1‡, Jamal Bamoulid[1,2], Yacine Benchikh[1], Jasper
Callemeyn[3], Mélanie Chaintreuil[4], Ludivine Dal Zuffo[1], Didier Ducloux[1,2], Imane Farhat[1,4], Mathieu
Legendre[4], Laurent Martin[1,5], Florian Renosi[1], Xavier Roussel[1], Thibaut Vaulet[3], Maarten Naesens[3],
Claire Tinel[1,4$], Baptiste Lamarthée[1$*]

Affiliations:

[1]Université Marie et Louis Pasteur, EFS BFC, Inserm UMR Right, Besançon, France

[2]Department of Nephrology, Dialysis and Renal Transplantation, Besançon University Hospital,
Besançon, France

[3]Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation
Research Group, KU Leuven, Leuven, Belgium

[4]Department of Nephrology and Kidney Transplantation, Dijon University Hospital, Université Bourgogne-
Europe, Dijon, France

[5]Department of Pathology, Dijon University Hospital, Université Bourgogne-Europe, Dijon, France

‡These authors equally contributed and share first authorship.
$These authors equally contributed and share last authorship

*Corresponding author.

Baptiste Lamarthée PhD

Phone: +33 3 81 615 615

8 rue du Dr Girod, Besançon, France

Email: baptiste.lamarthee@inserm.fr

29
30

Conflict of interest

The authors declare no conflict of interest regarding this manuscript.

Funding

MN is supported by the Research Foundation Flanders (F.W.O.) as senior clinical investigator (grant agreement no. 1844024N), MN is supported by a senior fundamental research project (grant agreement no. G038024N). TV and MN are supported by the Research Council of the KU Leuven (grant agreement no. C2M24057). BL is supported by the Agence Nationale de la Recherche (grant JCJC n°ANR-22-CE18-0011-01). CT is supported by the Agence de la Biomédecine (grant Recherche et Greffe 2024) and the Bourgogne Franche-Comté region (grant RECH-ANER "Initials").

Abstract

In solid organ transplantation, monocytes and macrophages play a cross-cutting role in the rejection process, irrespective of the transplanted tissue and the type of rejection. Here, we integrated multiple single-cell assays (>150,000 cells) with a broad spectrum of blood-derived and renal allograft-derived cells. We observed 6 myeloid cell trajectories enriched in the allograft during rejection, ranging from circulating CD14+ monocytes to differentiated macrophages in the kidney, with one trajectory culminating in a pro-inflammatory macrophage expressing *CXCL9* and *CXCL10*. By analyzing over 850 biopsies using deconvolution, we report that they are absent in pre-transplant allografts, while these *CXCL10*+ macrophages are the immune cells most associated with inflammation during acute rejection. Furthermore, a survival study of over 500 biopsies indicates that they increase the risk of graft loss independently of other immune cells. *CXCL10*+ macrophages differentiate from recipient monocytes, and we have identified 6 major genes associated with their differentiation, including *LILRB2*. In vitro, mimicking allogenic activation of blood monocytes via the CD47/SIRP-a axis induced overexpression of LILRB2, suggesting that *CXCL10*+ macrophages are activated by this pathway. Finally, we show that macrophages overexpressing LILRB2 induce the proliferation of autologous T lymphocytes. Altogether, the present study provides further insight into the pro-inflammatory axes of recipient-derived monocytes/macrophages, and suggests LILRB2 as a therapeutic target.

Introduction

In the field of solid organ transplantation, graft rejection remains one of the major challenges to ensuring the survival and optimal function of the transplanted organ. While this phenomenon is influenced by various cell types and immune mechanisms[1], monocytes and macrophages play a crucial and cross-cutting role in the rejection process, regardless of the transplanted tissue or histological picture of rejection[2]. A recent study has notably consolidated a vast amount of transcriptomic data from multiple solid organ transplants, including kidney, heart, liver, and lungs, revealing a common feature in the rejection of these organs: myeloid cell-driven inflammation[3]. This study identified the myeloid-derived CXCL9 and CXCL10 chemokines as central players in this inflammatory process, highlighting a shared mechanism of rejection across different transplanted tissues[4]. The ability of CXCL9 and CXCL10 chemokines to be induced in pan-organ rejection, is reflected by the fact that they form excellent biomarkers of rejection[5–8], as illustrated by their routine measurement in the urine of kidney transplant patients to monitor immune quiescence[9]. Interestingly, this research suggests that current phenotypes of rejection, against a background of T-cell targeted immunosuppression, does not longer appear to be primarily mediated by antibodies or T lymphocytes, but rather by monocytes and macrophages. Additionally, three decades of animal model research demonstrate that monocytes are not merely passive players in the immune response but are capable of directly recognizing allogeneic tissues[10]. These studies have showed that monocytes, independently of the adaptive immune response, can initiate[11] and sustain alloimmune rejection[12]. This capacity of monocytes and macrophages to act as primary drivers of histological lesions, through mechanisms outside the classic T and B cell responses[13] reinforces their central role in the immune response to pan-organ transplants. These findings challenge the prevailing understanding of rejection by the adaptive immune system and emphasize the central role of myeloid cells in the inflammatory response leading to graft failure.

Monocytes and macrophages are particularly involved through their ability to infiltrate the allograft, contributing to the initiation and amplification of the immune response and the progressive degradation of the graft. However, despite their recognized importance, the precise mechanisms by which circulating

monocytes, infiltrate the transplanted organ and differentiate into fully functional macrophages within the

renal graft remain largely unknown.

Here, we aimed to conduct an in-depth analysis of myeloid cell populations in the context of kidney graft

rejection. By leveraging single-cell sequencing technologies, we established a high-resolution cellular

profile of over 150,000 cells derived from the blood of 13 patients (including 5 without rejection and 8 with

rejection) and from kidney grafts of 33 patients (15 without rejection and 18 with rejection). We identified

differentiation trajectories from circulating monocytes to tissue-resident macrophages and we identified

key genes such as *FCN1*, *LILRA2*, *LILRB2*, *LILRA5*, *LST1* and *LY6E* involved in the differentiation of

proinflammatory macrophages driving graft rejection. Finally, we explored in vitro and in vivo the

significance of these molecules in allogeneic myeloid responses.

Methods

104
Single-cell RNA-sequencing data analysis

Main object generation:

The current study is a retrospective analysis of 46 publicly available single-cell RNASeq datasets from

kidney transplanted patients, either peripheral blood mononuclear cells (PBMCs) or allograft-derived cells

harvested from kidney biopsies. Raw data were downloaded either from the NCBI's Gene Expression

Omnibus database (accession number: GSE145927[14], GSE171374[15] and GSE140989[16]), from BioStudies

(accession number E-MTAB-11450[17] and E-MTAB-12051[18]) or from NCBI's BioProject (accession

number: PRJNA974568[19]). Count matrices were filtered using the following parameters: cells having <300

and >10,000 genes detected and circulating cells presenting >10% mitochondrial transcripts were

excluded whereas biopsy-derived cells presenting >25% mitochondrial transcripts were excluded. Filtered

gene expression matrices were then merged into a single object using the Seurat R package version

5.0.1[20], normalized with Seurat's NormalizeData function as well as scaled and centered using Seurat's

ScaleData function. The top 2,000 most variable genes were calculated with Seurat's

FindVariableFeatures function prior to calculating principal components (PC) using Seurat's RunPCA

function. Integration was performed using rpca method in Seurat's IntegrateLayers function[20], on the

supercomputer facilities of the Mésocentre de Franche-Comté. UMAP coordinates were calculated from

the top 50 PC using Seurat's RunUMAP function and visualized with Seurat's DimPlot function.

Unsupervised clustering was performed using Seurat's FindNeighbors and FindClusters functions with a

resolution of 0.47, which led to the identification of 23 distinct clusters. Cell types were annotated by

comparing the most differentially expressed genes (DEG) in each cluster, calculated using Seurat's

FindAllmarkers function, with canonical markers from the litterature[14–19,21–26]; some highly specific DEG

found in each cluster and previously unreported in the literature were also highlighted alongside canonical

markers. Dot plots and cell proportion barplots were generated using respectively the DotPlot_Heatmap

and Barplot_Cell_Proportion functions from the R package RightOmicsTools version 2.2.0[27], with

normalized counts as input data.

Myeloid cells reintegration:

Cells identified as monocytes, macrophages and cDC were subsetted from the main object and

reintegrated in order to determine their cell subtypes composition. Briefly, the top 2,000 most variable

genes were recalculated, prior to a new integration with rpca method. UMAP coordinates and

unsupervised clustering were calculated using Seurat's respective functions from the top 50 PC and a

resolution of 0.85, which led to the identification of 11 distinct clusters. Annotation was performed on

Seurat's FindAllMarkers top DEG in each cluster and compared to canonical markers from the literature[14–

19,28,29]. Seurat's FindMarkers function was used to find DEG between *SELENOP*+ macrophages and

CXCL10+ macrophages, and a volcano plot was built from the -log10 transformed false discovery rate

(FDR) adjusted p-values and the log2 fold change values for each gene using the R package ggplot2

version 3.5.1; the significance cutoff was set to a -log10 transformed FDR adjusted p-value of 15 and a

log2 fold chance below -1.5 or above 1.5.

Determination of myeloid cell origin:

Two genes' signatures were built from a set of 3 genes specific to either chromosome X (*XIST*, *JPX* and

FTX, thereafter designated as "female signature") or chromosome Y (*DDX3Y*, *KDM5D* and *USP9Y*,

thereafter designated as "male signature") and a module score was calculated on biopsy-derived

scRNASeq samples for each signature using the R package UCell version 2.6.2[30]. Datasets showing a

sex mismatch between the donor and the recipient with a clear opposing signatures expression observed

using the blend parameter of Seurat's FeaturePlot function were selected for further analysis: TAC1,

TAC2, TAC3, TAC4, BELA2, BELA3, GSM4339776, GSM4339779, EXT241, NEPH012, NEPH016,

NEPH017 and NEPH019. Cell identities were obtained from the blended FeaturePlot's ggplot2 object

using ggplot2's ggplot_build function and then matching the data (x and y coordinate values of the

scatterplot) of colored cells positive for either signature with UMAP's cell embeddings.

Cell-cell communication analysis

The R package CellChat version 2.1.2[31] was used to investigate ligands-receptors interactions between

cell types and unravel communication networks. Annotations from reintegrated myeloid cells were

transferred onto the same cells in the main object (matching cell barcode IDs from both objects) using

Seurat's SetIdent function. The CellChat database was appended to add interactions or modify existing

interactions based on published data[32–34]. A CellChat object was created from the normalized count matrix

and annotations of the main Seurat object and overexpressed genes, interactions, and communication

probabilities were computed using CellChat's respective functions identifyOverExpressedGenes,

identifyOverExpressedInteractions, computeCommunProb (with TriMean type), filterCommunication

(minimum 10 cells), computeCommunProbPathway, aggregateNet and netAnalysis_computeCentrality.

Incoming   and   outgoing   interaction   strength   were   visualized   using   CellChat's

netAnalysis_signalingRole_scatter function. Networks of ligands-receptors pairs were generated using

the cc_network function from the R package CCPlotR version 0.99.3[35]. Two other CellChat objects were

created by splitting the normalized count matrix into two matrices, based on the rejection status (no

rejection vs rejection). Overexpressed genes, interactions, and communication probabilities were

computed again using the same functions from CellChat, and both objects were then merged together. A

word cloud representing the most overexpressed ligands in each condition was built using CellChat's

computeEnrichmentScore function.

Trajectory inference analysis

174 The R package slingshot version 2.10.0[36] was used to explore trajectories/lineages in myeloid cells. The

175 cell embeddings matrix corresponding to UMAP coordinates of reintegrated myeloid cells was used as

input for pseudotime inference using slingshot's slingshot function, with classical monocytes as the

starting cluster. Custom functions were developed for trajectories visualization on UMAP coordinates

using ggplot2 , the R package patchwork version 1.2.0 and slingshot's slingPseudotime and slingCurves

functions to extract inference results data for plotting.

Trajectory-based differential expression analysis

The R package tradeSeq version 1.16.0[37] was used to find key genes significantly associated with each

trajectory identified by slingshot. The raw count matrix of reintegrated myeloid cells was filtered using the

RightOmicsTools' tradeSeqPreprocess function, keeping genes only expressed in more than 10 cells and

removing mitochondrial, ribosomal and non-coding genes, in order to reduce computational burden

without losing much information, poorly represented genes being unlikely to contribute; 13,981 genes

passed the selection. The filtered raw counts matrix as well as the slingshot output converted into a

SlingshotDataSet object were first used as input to tradeSeq's evaluateK function, which determines the

number of knots to fit on each trajectory for differential expression analysis. Upon selecting 5 knots based

on evaluteK results, the same input objects were then used to fit a negative binomial generalized additive

model (NB-GAM) for each gene on each trajectory using tradeSeq's fitGAM function on the

supercomputer facilities of the Mésocentre de Franche-Comté. Computation time was greatly reduced

using parallel computing from BiocParallel version 1.36.0 and batchtools version 0.9.17 R packages; a

custom Slurm template was created and used as input to BiocParallel's BatchtoolsParam function to take

advantage of the scheduler capacity to automatically divide calculations into individual jobs, submit them

in parallel to cluster nodes, and retrieve results from within the R environment. Within lineage DEG

comparison was performed using RightOmicsTools' tradeSeqTests function, which is a wrapper around

tradeSeq's earlyDETest adding FDR adjusted p-value and tidying the data, between knot 3 and 4 with

fitGAM results as input. A rank score was built from the results of each of these statistical tests,

corresponding   to

$(Wald\ statistic\ rank)^2 + (mean\ or\ median\ log2\ fold\ change\ rank)^2$ (as computed by the R base

rank function, with ties randomly broken) for each gene on each lineage or within lineage comparison,

and plotted alongside the log10 transformed Wald statistic values and log10 transformed mean or median

log2 fold change values for each gene using a custom ggplot2 code. Genes corresponding to the 90th

percentile and up in terms of rank score (as computed by the R package stats's quantile function, with 0.9

probability) from each lineage or within lineage comparison were selected and visualized on Venn

diagrams, produced using the R package venn version 1.12. Knots on trajectories were visualized on

UMAP coordinates using tradeSeq's plotGeneCount function and a custom ggplot2 code. Scatterplots,

smoothed gene expression curves and pseudotime heatmaps were generated respectively by the

RightOmicsTools' curveSmoothers and heatmapSmoothers functions.

Interrogation of the PROMAD atlas

The online atlas tool was used to retrieve relative expression data for *FCN1*, *LILRA2*, *LILRA5*, *LILRB2*,

LST1 and *LY6E* in kidney biopsies from the control or acute rejection groups

(https://shiny.maths.usyd.edu.au/PROMAD/). Only the 21 rejection datasets including the 6 genes of

interest were considered here. After selecting the datasets on the tool, the object in RDS format was

downloaded, and the expression data corresponding only to the 6 genes of interest were extracted in R.

These data were then statistically compared between groups using Prism software for each of the

datasets indicated using two-tailed Unpaired t test.

Determination of transcription factor activity

The R package decoupleR version 2.8.0[38] was used to infer the transcription factor (TF) activity between

SELENOP+ macrophages and *CXCL10*+ macrophages. The reference database, called CollecTRI[39],

containing a curated collection of TFs and their transcriptional targets, was built using decoupleR's

get_collectri function. Cells corresponding to *SELENOP*+ macrophages and *CXCL10*+ macrophages

were subsetted from the reintegrated myeloid cells and the normalized count matrix as well as the

CollecTRI object were used as input to the decoupleR's run_ulm function, which computes a score using

a Univariate Linear Model (ULM) for each TF in each cell based on the expression level of each TF's

transcriptional targets. This score reflects therefore the activity of a transcription factor based on the

expression of the genes it regulates. The ULM score results of 1318 TFs were stored as a matrix in a new

assay in the macrophages' Seurat object and scaled and centered using Seurat's ScaleData function.

The top 10 most differentially active TF in each of the two macrophage's subtypes were determined by

averaging each TF activity in each cell type, subtracting the mean *SELENOP*+ macrophages activity from

the mean *CXCL10*+ macrophages activity and selecting the first 10 and the last 10 TFs. Finally, the

RightOmicsTools' Cell_Heatmap function was used to visualize in the ULM assay the activity of these TFs

in each cell.

Deconvolution

The cellular composition of 1,374 publicly available kidney allograft biopsy microarray samples were

inferred by the CIBERSORTx algorithm[40] using the kidney allograft biopsy scRNAseq data from this work.

scRNAseq signature matrix construction and validation:

Annotations from reintegrated myeloid cells identified as classical monocytes, intermediate and non-

classical monocytes, as well as *SELENOP*+ macrophages and *CXCL10*+ macrophages were transferred

onto the same cells in the main object (matching cell barcode IDs from both objects) using Seurat's

SetIdent function. Cells originating from kidney allograft biopsies were subsetted from the main object and

the raw count matrix was normalized to Counts Per Million (CPM) with Seurat's NormalizeData function

using the Relative Counts (RC) normalization method and a scale factor of 1,000,000. The

benchmarking_init function from the R package deconvBenchmarking version 0.1.0[41] was used to divide

the normalized count matrix into a training matrix, composed of 5% of cells randomly selected from each

cell type, thus maintaining the original proportions of cell types within the original matrix, and a validation

matrix, created using the remaining 95% of cells, whose expression was averaged per cell type and

randomly distributed into 100 simulated pseudobulk mixtures (constituting the ground truth). The random

cell type composition is known and varies for each of the 100 mixtures to benchmark CIBERSORTx

performance. The training and validation matrices were exported as tab-separated text files using

respectively the create_cibersortx_input parameter of deconvBenchmarking's benchmarking_init function

and RightOmicsTools' Mixture_File_Builder function, and uploaded into the web interface of

CIBERSORTx. The training matrix was used as input to the "Create Signature Matrix" module of

CIBERSORTx. Given that a droplet-based technique (10X Chromium) was used for generating the

scRNAseq datasets, the *Min. Expression value* parameter was reduced to 0.25. This adjustment aims to

increase the reliability of the signature matrix, as recommended by CIBERSORTx, resulting in a matrix

consisting of 6172 genes and 23 cell types. The signature matrix and the validation matrix were then used

as input to the "Inpute Cell Fractions" module of CIBERSORTx to estimate the cell proportions of the

simulated pseudobulk mixtures, using *S-mode* batch correction and 100 permutations for statistical

significance. A Pearson's correlation coefficient was calculated for each cell type by comparing the

estimated cellular composition from CIBERSORTx to the simulated pseudobulk mixtures' ground truth in

order to validate the signature matrix.

<u>Cellular composition estimation of microarray data:</u>

Six publicly available microarray datasets were downloaded from the NCBI's GEO FTP servers

(accession numbers: GSE21374[42], GSE36059[43], GSE48581[44], GSE98320[45], GSE147089[46] and

GSE147451[47]) as gunzipped text files. After extraction, the text files were divided into metadata and

expression matrix. For the GSE36059 and GSE48581 datasets, samples corresponding to ABMR, TCMR

and Mixed were selected. For the GSE98320 dataset, the Borderline and ABMRsusp. samples were

excluded. For the GSE147089 dataset, two samples with missing survival data were excluded. The probe

ID of each gene was converted into its matching ENSEMBL ID using the R package oligo version 1.66.0

and the corresponding Affymetrix database. The six expression matrices were then loaded into BIOMEX

software version 1.0.5[48] to map the ENSEMBL IDs into HGNC symbols. Finally, since the expression

matrices were already log2-RMA normalized, they were not further processed and were exported and

converted into tab-separated text files using the RightOmicsTools' Mixture_File_Builder function and

uploaded into the web interface of CIBERSORTx. The validated signature matrix and each expression

matrix were then used as input to the "Inpute Cell Fractions" module of CIBERSORTx, using *S-mode*

batch correction and 100 permutations for statistical significance. Various custom ggplot2 codes were

employed to visualize the cell proportions as box plots, bar plots, scatter plots and violin plots. Radar

plots were generated using the radarchart function from the R package fmsb version 0.7.6.

M1 and M2 macrophages bulk RNA-sequencing data analysis

Raw data were downloaded from the NCBI's GEO database (accession number: GSE146028[49]) and

loaded into BIOMEX software version 1.0.5[48]. Metadata corresponding to macrophages M1 and M2

subtypes were added, counts were normalized. A volcano plot of M1 vs M2 comparison was generated,

DEG results used to build the plot (log2 fold change, p-value and FDR adjusted p-value) were exported

into R and the volcano plot was reconstructed from these values using ggplot2; the significance cutoff

was set to a -log10 transformed FDR adjusted p-value of 2 and a log2 fold chance below -1.5 or above

1.5. Genes found to be significant on the volcano plot between *SELENOP*+ and *CXCL10*+ macrophages

were represented and four quadrans were drawn depending on significance cutoff, with a fifth area

representing no significance.

Isolation of PBMC by density gradient

Peripheral blood from Buffy coats (Etablissement Français du Sang-BFC, France) was filtered through a

70µm strainer. Two volumes of blood were poured onto one volume of Lymphocyte separation medium

(Eurobio Scientific, Les Ulis, France). Cells were then centrifuged for 30 min at 800g at room temperature.

PBMC were washed with Phosphate-Buffered Saline (PBS, Thermofisher, Courtaboeuf, France) by

centrifugation at 450g at 4°C for 5min. The cell pellet was resuspended in PBS, then centrifuged at 2100g

for 2min at 4°C to remove the platelets.

Flow cytometry analysis

Samples to be analyzed by flow cytometry were centrifuged at 700g 5min at room temperature. One

million cells from each condition were labeled with fluorochrome-coupled antibody for 15min at 4°C. Prior

to cytometric analysis, labeled cells were washed with 2mL PBS and centrifuged at 700g 5min at room

temperature before being resuspended in 200 μL PBS for analysis on a DxFlex cytometer (Beckman

Coulter, Paris, France) or an Attune cytometer (Thermofisher). The following antibodies were used: anti-

LILRB2 PE-Vio 770 (REA184, Miltenyi Biotec), anti-CD16 BV605 (3G8, Biolegend). When indicated,

incubation with Fixable Viability Stain 700 (BD Biosciences, Paris, France) was performed prior to

incubation with the coupled antibodies according to the supplier's recommendations.

Monocyte sorting

Monocytes were magnetically sorted from PBMC either by the CD14 Microbeads kit for transduction

experiments or by the PanMonocyte kit (Miltenyi Biotec, Paris, France) for in vitro activation experiments

following the supplier's recommendations. A minimum purity of over 85% was required to start the

experiments.

Monocyte activation

Anti-CD47 (PA5-80435, Thermofisher) and a non-specific control antibody (10500C, Thermofisher) were

coated in a 12-well plate (3413, Corning) for 4h at 37°C at a concentration of 3μg/mL in PBS. The wells

were then emptied and 0.5.106 purified monocytes suspended in 1mL of warm RPMI supplemented with

10% FBS and 1% Pen/Strep medium were deposited in each well before spinoculation for 1min at 100g,

followed by incubation at 37°C with 5% CO_2.

Lentiviral transduction

To induce expression of the LILRB2 in THP-1, we used lentiviral strategy (VectorBuilder, Neu-Isenburg,

Germany) with a lentivirus encoding *LILRB2* and a reporter gene encoding *TagGFP2*. THP-1 were

transduced at a multiplicity of infection (MOI) of 2.5 in the presence of 8 mg/L Polybrene (PL001,

VectorBuilder). Briefly, $0.5.10^6$ cells per well were seeded in P24 well plate in the presence of virus

particles and Polybrene. Control wells contained only $0.5.10^6$ cells/well and culture medium. The

transduction was performed by spinoculation, i.e. centrifugation at 32°C, 1000 g for 90 minutes before

culture for 2 days. To induce expression of the LILRB2 in human primary macrophages, monocytes

freshly isolated from healthy volunteers were subjected to M0 differentiation by M-CSF (130-096-492,

Miltenyi Biotec) at 25ng/mL in X-Vivo medium (BEBP02-054Q, Lonza, Colmar, France) supplemented

with 10% of FBS (10271-106, Gibco) for 2 days before transduction with virus-like particles packaging

Vpx to overcome virus restriction[50]. The production of Vpx particles was performed as previously

described[51]. At day 4 of culture, the cells were transduced with the lentivirus encoding *LILRB2* and

TagBFP2 at MOI 1. At day 10 of culture, the fully differentiated macrophages were collected for cytometry

analysis and LILRB2-HLA interactions assay.

FACS isolation of THP-1 clones

Cell sorting of transduced THP-1s was performed using a BDFACS ARIA III sorter (BD Biosciences,

Paris, France) at the ImaFlow Platform (Dijon, France). THP-1 cells were labelled with an anti-LILRB2 PE

Vio 770. The clones expressing different levels of the reporter gene TagBFP2 were selected and sorted in

a 96-well plate pre-filled with culture medium to obtain one single clone per well. Identification of each

clone according to the expression levels of LILRB2 was performed on FlowJo software using the Index

Sort plugin (BD Biosciences).

LILRB2-HLA interaction assay

352 In order to assess LILRB2-HLA interaction, cells of interest were incubated with HLA-B27-APC pentamer

353 (F294-4B-E, ProImmune, Oxford, UK) or HLA-A2-A2-PE pentamer (F10-2B-E, ProImmune) according to

354 the supplier's recommendations.

ORLY-EST ancillary cohort

ORLY-Est (Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation, NCT02843867) is a prospective cohort study of kidney transplant patients included in seven French transplant centers (Besançon, Clermont-Ferrand, Dijon, Le Kremlin-Bicêtre, Nancy, Reims and Strasbourg), whose main objective was to understand the interactions between immune status and post-transplant outcomes. For each patient, blood samples were collected on the day of transplantation (d0) and one year later (d365). Peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation (Pancoll, Pan-Biotech GmBH Aidenbach, Germany) and stored in liquid nitrogen at the Centre de Ressources Biologiques Ferdinand Cabanne (Dijon, France). Samples were collected with the regulatory approval of the French Ministry of Health (agreement number DC-2008-713 dated June 11, 2009), and the study was approved by the ethics committee of the Université de Franche-Comté in 2008. All patients included in the ORLY-Est study were of legal age at the time of transplantation, and gave written informed consent. For this ancillary present study, PBMC were stained for flow cytometry analysis as previously described in an 8-batch sequence including a common healthy PBMC for batch normalization. To ensure analysis quality, cytometry files were normalized between batches using the CytoNorm[52] plugin, and abnormal events intrinsic to cytometry were removed using the FlowClean[53] plugin.

Inflammation level analysis

A diagnostic label was awarded to each biopsy based on the presence and severity of these histological lesions and on the DSA status. In this aim, all biopsies were categorized into one of six recently described clinicopathological categories[54], based on the presence of acute histological lesions and recipient DSA status (available at https://rejectionclass.eu.pythonanywhere.com/). This data-driven classification allows for visualization of the biopsies on a two-dimensional polar plot in which the theta angle associates with the spatial localization of the inflammation, i.e., microvascular inflammation versus tubulointerstitial

381   inflammation. The radius indicates the global severity of the inflammatory infiltrate given by the sum of re-

382   weighted acute lesions scores, scaled to the unit interval (from 0 to 1) and is hereafter designated as

383   "Activity index"[54,55].

Autologous T Cell Proliferation Assays

On the day of monocyte sorting, the remaining PBMC from the same donors were cultured in complete

RPMI supplemented with IL-2. To achieve coculture with syngeneic macrophages, PBMCs were stained

with Cell Trace Red according to the manufacturer's procedure (Cell Trace, Thermofisher). Labeled cells

were cultured with human CD3/CD28 T activator beads (Dynabeads, Thermofisher) in a 96-well UBottom

plate in 100µL of complete RPMI at $1,10^6$ cells/mL with or without 100µL of macrophages. For dose-

dependent experiments, the number of labeled PBMC was fixed, while the number of macrophages

varied from a ratio of 1:1 to 1:4 (macrophages:PBMC). T-cell division was detected after 5 days by flow

cytometry and analyzed using the Proliferation module of FlowJo software.

Statistical analysis

We report descriptive statistics using mean and standard deviation (or median and interquartile range for

skewed distributions) for continuous variables or numbers, and percentages for discrete variables, for the

full cohort and for the rejection subgroups. We used the most recent (as of July 2025) versions of all

software programs, including R Studio (version 2025.05.0+496) and Prism (version 10; GraphPad

Software, San Diego, CA, United States) for statistical analysis and data presentation. The time-

dependent ROC curve analysis of survival data was performed with the function survivalROC from the R

package survivalROC version 1.0.3.1[56] at 365 days post biopsy and using the Kaplan-Meier (KM)

method. The Youden index[57] was computed from the specificity and sensitivity values of the model, as

defined by the formula $sensitivity + specificity - 1$ for each cell type and represented using a custom

gpplot2 code. The Kaplan-Meier survival curves[58] right-censored at 1825 days post biopsy were

generated using the survfit and Surv functions from the R package survival version 3.5-7[59] and visualized

with the ggsurvplot function from the R package survminer version 0.5.0[60]. Cox proportional hazards

analysis of survival data right-censored at 365 days post biopsy was performed using survival's coxph

function and visualized using survminer's ggforest function.

Results

412
Single-cell integration of kidney allograft and blood-derived cells

To characterize the infiltration of circulating monocytes and their differentiation into macrophages in

kidney transplant patients, we integrated 46 single-cell RNA-Seq datasets, including 13 datasets

corresponding to blood-derived cells (including N=5 without rejection and N=8 rejections) and 33 datasets

corresponding to kidney allograft-derived cells (including N=13 without rejection and N=20 rejections, Fig.

1A). The rejection phenotypes were diverse from a histological point of view and showed varying levels of

inflammation, ranging from mild to severe. In addition, for N=3 patients, including two cases of rejection,

we were able to integrate both blood cells and cells from the kidney allograft collected on the same day,

contributing to the robustness of the results (Fig. 1B). After passing quality controls (Fig. S1a), we

successfully integrated 150,876 transcriptomes without any major batch effects, whether between

datasets, tissue of origin, or between the rejection group compared to the non-rejection group (Fig. S1b).

In an unsupervised manner, 23 different clusters were identified, corresponding to blood and kidney cells.

The annotation using canonical and unsupervised markers (Fig. 1C, Supplemental Table 1) of these

clusters led to the identification of immune cells subtypes such as *S100A12+ LYZ+ CD14+* monocytes

and *C1QA+ C1QB+ MS4A4A+* macrophages (Fig. 1D). When comparing the proportion of immune cells

between the rejection and non-rejection groups within the allograft, an increase in the proportion of

immune cells was observed in cases of rejection, as expected. Notably, the proportion of macrophages

within the allograft increased from 1.19% in non-rejection to 3.95% in cases of rejection (Fig. 1E). A

global, unsupervised comparison of the main cellular interactions between rejection and non-rejection on

all integrated cells reveals that the no rejection group is mainly associated with CCL5 and LGALS9 (Fig.

1F). In contrast, the rejection group is predominantly associated with CXCL10 and CXCL9 in line with

recently reported pan-organ transcriptomic data across organs, which confirms that CXCL9 and CXL10

chemokines are central in rejection process[3] and underscore the ubiquitous role of myeloid cells in solid-

organ transplantation[4].

A pro-inflammatory macrophage subpopulation expressing *CXCL10* is specifically enriched

during rejection

We then selected all the myeloid cells annotated previously as 'Monocyte', 'Macrophage' and 'cDC' (Fig.

1D) for reintegration, in order to better understand the heterogeneity of myeloid cells, both in the blood

and infiltrating the allograft after kidney transplantation. We thus obtained 11 different clusters in an

unsupervised manner (Fig. 2A). Among them, we identified in an unsupervised approach 6 monocyte

populations and their specific markers (Supplemental Table 2), such as *S100A12+ CD14+ LYZ+* classical

monocytes, a *MARCO+ APOBEC3A+* population of intermediate monocytes, an *IFIT1+ HERC5+ MX1+*

population of IFN-activated monocytes, a *FCGR3A+ CDKN1C+* non-classical monocyte population, a

PECAM1+ CX3CR1+ TCF7L2+ patrolling monocyte population, and a monocyte population differentiating

into dendritic cells, the mo-DCs expressing *AHNAK* and *HIST1H1E*. In addition, 3 populations of dendritic

cells were detected: a *CLEC10A+ CD1C+ FCER1A+* conventional type 2 DC (cDC2), a *CLEC9A+*

XCR1+ GCSAM+ cDC1 population and a *TNF+ CCL3L1+ CD83+* population named hereafter "CD83

mature DC". Finally, 2 subtypes of macrophages were distinguished from all other myeloid cells: a

SELENOP+ STAB1+ TREM2+ population and a *CXCL10+ ANKRD22+* population (Fig. 2B). Concerning

the proportion of the overall myeloid compartment detected within allografts, we observed a substantial

increase with a doubling of the global myeloid population during rejection (Fig. 2C) in line with previous

reports[2,61]. More specifically, the infiltration ratio of myeloid cells differed according to their subtypes.

While the proportion of cDC1, cDC2, CD83+ DC, mo-DC and patrolling monocyte was not enriched in

allograft, the proportion of *CXCL10+* macrophages, classical, intermediate and IFN-activated monocytes

and *SELENOP+* macrophages was statistically increased in rejection. In particular, a 5-fold increase in

the proportion of *CXCL10+* macrophages was observed, indicating a major enrichment of this population

within the kidney allograft during rejection (Fig. 2D). Among myeloid cells detected solely within the

allograft, the proportion of *CXCL10+* macrophages increased significantly in rejection (0.0% vs 6.4%,

P=0.0009) compared with *SELENOP+* macrophages (29.2% vs 25.4%, P=0.68) suggesting that not only

infiltration but also differentiation of this population is directly associated with the allogeneic response

against the graft (Fig. 2E).

CXCL10+ and SELENOP+ macrophages harbor distinct transcriptomic programs

By comparing the transcriptomic profiles of the two macrophage populations (*CXCL10*+ and *SELENOP*+),

we observed that *CXCL10*+ macrophages also overexpressed 112 signature genes, including

proinflammatory genes such as *WARS*, *CXCL9*, *GBP1*, *GBP2* and *GBP5* which have previously been

described as major biopsy-derived transcripts associated with rejection[62] (Fig. 2F). It is noteworthy that

among these signature genes of *CXCL10*+ macrophages, a third is included in the Banff Human Organ

Transplant (B-HOT) probe set panel[63] including pertinent genes related to rejection and innate and

adaptive immune responses (N=36/112, Supplemental Table 3). Moreover, they specifically express

genes encoding LILR receptors, some of which, such as LILRB1 and LILRB2, can bind HLA molecules[64].

We then identified the transcription factors (TFs) potentially involved in DEG regulation in both sub-

populations. In particular, *SELENOP*+ macrophages express TFs from the NR1H family of nuclear

receptors, namely *NR1H4* (FXR), *NR1H3* (LXRα) and *NR1H2* (LXRβ), which regulate lipid homeostasis[65].

In turn, *CXCL10*+ macrophages strongly express TFs of the Interferon Regulatory Factors (IRFs) family,

notably *IRF3*, which induces *CXCL10* expression independently of IFN-γ activation[66]. In a reductive

manner, macrophage subtypes have historically been stratified according to pro-inflammatory M1[67] and

pro-fibrotic M2[68] profiles obtained after in vitro differentiation from monocytes. We compared the

transcriptomic profiles of *CXCL10*+ and *SELENOP*+ macrophages identified in vivo with M1 and M2

macrophages generated in vitro[49]. In *CXCL10*+ macrophages, 71.8% of their signature genes

corresponded to genes upregulated in M1, revealing around 30% of "discordant" genes, including

S100A4 and S100A6, responsible for cell mobility. As for *SELENOP*+ macrophages, only 32.7% of their

signature genes were shared with M2, suggesting that the historical stratification between M1 and M2

derived from in vitro experiments is too limited and cannot be directly matched to macrophage subtypes

described in vivo[69] (Fig. S2a). We then examined the origin of the two types of macrophages using the

expression of X-linked genes or Y-linked genes as previously described in patients who had received a

transplant from a sex other than their own[70]. Unambiguously, we observed that 100% of *CXCL10*+

macrophages originated from the recipient, suggesting that the presence of these cells entirely relies on

infiltration by circulating monocytes. *SELENOP*+ macrophages, on the other hand, comprise around 18%

donor-derived cells and 82% recipient-derived cells, so partly tissue-resident (Fig. S2b). A comparison of

the markers of these two subsets revealed that donor-derived *SELENOP*+ are *SELENOPhi* and *TREM2*-,

while recipient-derived *SELENOP*+ are *SELENOPlow* and *TREM2*+ (Fig. S2c). In term of cellular

interactions predicted at transcriptomic level between *CXCL10*+ and *SELENOP*+ macrophages and their

microenvironment in the allograft, we detected more than 35 significantly enriched incoming signaling and

more than 40 outgoing signaling (Fig. S2d). Among incoming signaling, we notably detected cell-contact

CD47-SIRPA and LILRA1-B1-B2-class I HLA signaling which have been reported as responsible of

allogeneic myeloid response in the animal[71,72] but also PECAM1-CD38, the interaction which is required

for leukocyte transendothelial migration suggesting that the *CXCL10*+ macrophages derive from recipient-

derived monocytes. In contrast, PECAM1-CD38 interaction was not detected in *SELENOP*+

macrophages suggesting that this population is less susceptible to derive from monocyte infiltrating the

allograft through proinflammatory chemokine gradient (Fig. S2b). In term of cytokine-receptors, *CXCL10*+

macrophages mainly receive TNF signaling through TNF-TNFRSF1 but also chemokines through CCL-

CCR1. In return, *CXCL10*+ macrophages outgoing signaling is characterized by CXCL-receptors

signaling and TNF signaling, suggesting both cis and trans-signaling through this pathway. Altogether

these results suggest that the *CXCL10*+ macrophages derive exclusively from the recipient and infiltrate

the allograft to induce severe inflammation.

CXCL10+ macrophages are specifically generated during the allograft response and cause acute rejection

In order to generalize our initial results to much larger external cohorts, we used the tool of deconvolution

to estimate the fraction of *CXCL10*+ macrophages in pre- or post-transplant renal grafts. To this end, we

reanalyzed datasets corresponding to N=192 preimplantation biopsies, N=489 post-transplant renal

biopsies for which Banff lesions were available and N=189 post-transplant renal biopsies for which the

rejection subtypes were available (Fig.3a). Strikingly, no *CXCL10*+ macrophages were detected in pre-

transplant biopsies (median = 0.000% of total allograft cells), while a very limited contingent of these cells

was measured in biopsies showing no major abnormalities (No MOA) or atrophy-fibrosis (IFTA) (median =

0.003 % and 0.000% respectively, Fig.3b). In contrast, biopsies depicting allogeneic rejection showed a

significant increase of *CXCL10*+ macrophages with respectively a median of 0.84 % of *CXCL10*+

macrophages in AMR, 1.55 % in TCMR and 1.47% in mixed rejection. Conversely, in pre-implantation

biopsies, the proportion of other myeloid cell types, such as *SELENOP*+ macrophages or cDCs, is at the

same level as in No MOA, IFTA or AMR biopsies, suggesting that these cells are all detectable in the

graft at the time of transplantation (Fig. S3a). These results confirm that, unlike other myeloid cells,

CXCL10+ macrophages originate from the recipient and infiltrate the graft only during acute rejection and

not in other contexts such as fibrosis. To clarify the association between *CXCL10*+ macrophage

infiltration and the intensity of inflammation during rejection, we measured the rejection activity index as

previously described[54]. We first observe considerable heterogeneity in biopsy profiles (Fig.S3b) and that,

irrespective of rejection subtypes, the proportion of *CXCL10*+ macrophages measured in biopsies was

strongly correlated with the acute rejection level given by the sum of g+ptc+i+t Banff lesions (Fig.3c) and

inflammation given by the rejection activity index (Fig.S3c). We then compared the correlation between

inflammation and other cell types, and found that *CXCL10*+ macrophages were the immune cells most

positively correlated with inflammation, followed by NK, cDC and CD8 T cells (Fig.S3d). By stratifying

biopsies according to Banff lesion scores characterizing rejection, the proportion of *CXCL10*+

macrophages gradually increase in the presence of glomerulitis, peritubular capillaritis, interstitial

inflammation, intimal arteritis, tubulitis and C4d deposition (Fig.3d). Comparing to other myeloid cell types,

their fold change in biopsies showing presence of acute rejection lesions was considerable (Fig.S3e). We

then investigated whether *CXCL10*+ macrophage infiltration was associated with graft outcome.

CXCL10+ macrophage levels were measured by deconvolution in 504 post-transplant biopsies (Fig.4a).

At 1-year post-biopsy, the maximum Youden index (J_{max}) was calculated, indicating that a proportion of

0.984% *CXCL10*+ macrophages discriminated between patients with significantly different graft survival

(Fig.4b). Biopsies were then stratified into two groups: those in which more than 0.984% *CXCL10*+

macrophages were found, and those in which less than 0.984% of allograft cells were *CXCL10*+

macrophages. The detection in the biopsy of more than 0.984% of *CXCL10*+ macrophages infiltrating the

allograft resulted in a significant decrease of the graft survival (Fig.4c, Log-rank P-value <0.0001). We

then performed a univariate Cox regression and observed that the proportion of *CXCL10*+ macrophages

measured in the biopsy was significantly related to the risk of subsequent graft loss (hazard ratio, 4.97;

95% CI, 2.7 to 9.15; P<0.0001). Of note, NK cells, CD8 T cells and cDC, the other cell types associated

with inflammation (Fig.S3d), were also significantly associated with the risk of graft loss. Importantly, we

built a multivariate Cox regression model (Fig.4d) that confirmed that patients with high *CXCL10*+

macrophages proportion infiltrating the allograft had a higher risk of graft loss than those with fewer

CXCL10+ macrophages (hazard ratio, 2.64; 95% CI, 1.26 to 5.5; P=0.01) independently of NK cells, CD8

T cells and cDC. Overall, these results suggest that, after transplantation, pro-inflammatory *CXCL10*+

macrophages from the recipient infiltrate the allograft and induce microvascular and interstitial lesions,

contributing to graft loss, independently of other immune cells.

Myeloid cells differentiation is driven by six main trajectories in kidney transplant recipients

In order to better characterize the origin of the *CXCL10*+ macrophages, we next built unsupervised

pseudotime trajectories among myeloid cells. In the interests of transparency and reproducibility, our

entire monocyte trajectory construction pipeline is publicly available. All of these trajectories originated

from blood-derived classical monocytes and formed a branch at the level of intermediate monocytes,

before being distributed in clusters of fully differentiated cells such as DCs and macrophages within the

allograft, or as non-classical or patrolling monocytes which were detected in both blood and allograft (Fig.

5a). These data suggest that classical monocytes can differentiate into intermediate and then non-

classical monocytes as is also the case in the event of systemic inflammation[73]. Surprisingly, one of the

trajectories formed a loop passing through CD83 mature DC and back to classical monocytes. Moreover,

the six trajectories begin to separate at the branching point annotated "3" corresponding to intermediate

monocytes. We therefore wanted to investigate which transcripts were specific to segment 3-4 of the

branched section corresponding to *CXCL10*+ macrophages. For this purpose, we compared the

transcripts associated with segment 3-4 of each trajectory (Fig. 5b) considering only the most specific

transcripts (Rank score>q90). We intersected the transcripts of each comparison and defined 22

transcripts which were highly associated to segment 3-4 of CXCL10+ macrophages (Fig. 5c). Among

these 22 transcripts, 6 of them, *FCN1*, *LY6E*, *LILRA2*, *LILRB2*, *LST1* and *LILRA5* shared a similar profile

and high expression (Fig. 5d). In order to confirm the increased expression of these 6 genes during

rejection in external global transcriptomics datasets, we queried the PROMAD atlas[3] (Fig. S4a). In 21

external datasets encompassing the 6 genes of interest and representing over 2,500 biopsies, *FCN1* and

LST1 expression was found to be systematically significantly increased in the graft during rejection except

in two datasets. *LILRA2* was significantly increased in 18/21 datasets, and *LILRB2* in 15/21 datasets,

confirming the importance of these transcripts during rejection. *LILRA5* and *LY6E*, on the other hand,

were only significantly increased in 7/21 datasets indicating that they may be more specific to a subtype

of immune response (Fig. S4b). Plotting the expression of these genes along trajectories, we confirmed

the specificity of these transcripts the *CXCL10*+ macrophages trajectory. Surprisingly, we also observed

that *LILRB2*, *LILRA5* together with *LILRA2* transcripts were upregulated at the end of the CD83 mature

DC trajectory back to classical monocytes (Fig. 5e). In mice, myeloid allorecognition is primed by

CD47/SIRP-⍺ axis[71] and leads to the overexpression of paired immunoglobulin receptors (PIRs) at

myeloid cell surface[72]. The human orthologs of PIRs are leukocyte immunoglobulin-like receptors (LILRs).

Here, our data suggest that the trajectory of *CXCL10*+ macrophages relies on three LILRs, *LILRB2*,

LILRA2 and *LILRA5*, but also that recirculating monocytes may retain the imprint of their passage through

the allograft. We therefore expanded our analysis to the other LILRs and observed that *LILRA1*, *LILRB1*

and *LILRB3* also follow the same expression profiles: they are strongly increased in *CXCL10*+

macrophages and they are upregulated at the end of the trajectory returning to classical macrophages

(Fig. S5).

We then investigated whether this activated state due to the allogeneic responses could be captured in

the blood of kidney transplant recipients. For this purpose, we built an ancillary cohort to the ORLY-EST

cohort of kidney transplant recipients[74]. For each patient, a blood sample was collected on the day of

transplantation (d0) and one year later (d365) (Fig. 6a). We therefore gathered N=64 patients with a pair

of available PBMC samples (Fig. S6a). Of these patients, 8 showed mild to very severe rejection during

the first year of transplantation (Fig. S6b). In order to perform a cytometric analysis limiting the potential

batch effect, we followed a robust pipeline including batch correction and normalization (Fig. S6c). We

then applied a gating strategy using CD14 and CD16 markers to select CD14+CD16- classical

monocytes, CD14+CD16+ intermediate monocytes and CD14-CD16+ non-classical monocytes (Fig.

S6d). By comparing the kinetics of LILRA1, LILRA2, LILRA5, LILRB1 LILRB2 and LILRB3 expression in

these 3 populations between before transplantation and one year after, we observed that LILRA2

(GeoMFI$_{d0}$ = 509 vs GeoMFI$_{d365}$ = 626, P=0.046), LILRB1 (GeoMFI$_{d0}$ = 565 vs GeoMFI$_{d365}$ = 699,

P=0.035) and LILRB2 (GeoMFI$_{d0}$ = 1369 vs GeoMFI$_{d365}$ = 1737, P=0.032) expression increases

significantly in classical monocytes from patients with rejection compared with those without rejection.

Moreover, this increase was not observed in intermediate or non-classical monocytes (Fig. 6b).

Altogether, these results suggest that upon rejection, classical monocytes could differentiate into

CXCL10+ macrophages and infiltrate the allograft or recirculate with the imprint of allogeneic activation.

Allogeneic activation of classical monocytes leads to increased expression of LILRB2

Recent data from allogeneic recognition models in mice suggest that allogeneic monocytes are activated

via the CD47-SIRP-▢ axis[71]. We hypothesized that this activation could drive the differentiation of

recipient-derived monocytes into *CXCL10*+ macrophages. To recapitulate the impact of the allogeneic

activation in circulating classical monocytes within the allograft, we thus activated them *in vitro* by the

CD47-SIRP-▢ axis. For this purpose, classical monocytes were isolated from the blood of healthy

volunteers and an immunological synapse was artificially mimicked as is widely and historically done for T

cells by activating their CD3 and CD28 receptors with antibodies coated onto the culture plastic[75]. Here,

we used polyclonal antibodies targeting CD47, essential for myeloid allo-activation[10] and measured the

impact of these activations at protein levels after 48h of culture (Fig. 7a).

Forty-eight hours after activation, LILRA2 was not differentially expressed at cell surface. In contrast,

LILRB2 and LILRA5 were significantly increased after stimulation of CD47 (GeoMFI$_{Ig}$ = 74975 vs

GeoMFI$_{CD47}$ = 99030, P=0.0273 for LILRB2 and GeoMFI$_{Ig}$ = 1439 vs GeoMFI$_{CD47}$ = 2338, P=0.0137 for

LILRA5) compared with control condition. The expression of CD16 (GeoMFI$_{Ig}$ = 6314 vs GeoMFI$_{CD47}$ =

12952, P=0. 0371) was also doubled after CD47 stimulation. Surprisingly, LILRB1 expression was

significantly decreased (GeoMFI$_{Ig}$ = 26987 vs GeoMFI$_{CD47}$ = 20437, P=0.0059 , Fig. 5B-C). Altogether

these results suggest that the allogeneic recognition of SIRP-▢ via CD47 induces specifically certain

LILRs such as LILRB2 and the differentiation from classical CD14+CD16- to intermediate CD14+CD16+

phenotype before macrophage differentiation.

Of note, SIRPA expression was primarily reported in myeloid cells but could also be detected in renal

cells such as podocytes[76–78]. In addition, our cell-cell contact analysis suggested that CD47-SIRP-⍺

signaling in *CXCL10*+ macrophages relies on *SIRPA* expression in both *SELENOP*+ macrophages and

PT_injured cells (Fig. S2d). We thus assessed the expression of SIRPA across all renal cell types and we

confirmed that *SIRPA* is expressed in both podocytes and injured PT cells notably upon rejection (Fig.

S7). These results suggest that *CXCL10*+ macrophages could continue to be activated through CD47-

SIRP-⍺ in the tubulointerstitial compartment or in the damaged glomeruli within the allograft in addition to

LILRs ligation.

Macrophages overexpressing LILRB2 bind HLA class I molecules, triggering their activation

We then wanted to explore the impact of LILRB2 overexpression in macrophages. To do this, we started

with a human myeloid cell line, the THP-1 cell line[79], which, according to a previous report, lost LILRB2

expression on its surface compared with primary human monocytes[80]. We set up a transduction strategy

with lentiviral vector encoding *LILRB2* and a reported gene, *TagBFP2* (Fig. S8a). We then successfully

isolated TagBFP2+ single cell clones by FACS and therefore generated 2 clones, D02 and G02, of THP-1

expressing high level of LILRB2 (Fig. S8b). As LILRB2 is known to bind to class HLA molecules present

on the cell surface, unlike LILRA2 or LILRA5 [81,82], we next assessed whether LILRB2 overexpression

could lead to a modulation of binding with HLA. Historically, THP-1 were described as HLA-A2+ and HLA-

B5+[79]. We therefore verified that THP-1 express HLA-A2 and not HLA-B27 (Fig. S8c) and we then tested

the LILRB2-MHC interaction in THP-1 WT and clones D02 and G02. In THP-1 WT that do not express

LILRB2, binding to self HLA (assessed by HLA-A2 pentamers) or non self HLA (HLA-B27 pentamers) is

undetectable. In contrast, in LILRB2 overexpressing clones D02 and G02, we detected fixation of both

self and non-self HLA (Fig. S8d).

One of the limitations of the THP-1 model is inherent in the malignant nature of this cell line. We thus

assessed the capacity of LILRB2-HLA interactions in *bona fide* primary human macrophages. In this aim,

we adapted a similar lentiviral strategy in freshly isolated monocytes (Fig. 8a). After 10 days of M0

differentiation, we measured the expression of both TagBFP2 and LILRB2 in the transduced

macrophages and observed a significant increase of the percentage of LILRB2hi cells (Fig. 8b-c)

compared with non-transduced control (Median percent$_{NT}$ = 0.00 vs Median percent$_{LILRB2}$ = 53.90 ;

P=0.0022). We applied the same LILRB2-HLA interactions assay using HLA-A2 and HLA-B27 pentamers

and were able to detect class I HLA binding on LILRB2hi macrophages (Fig. 8d). We confirmed that

LILRB2 overexpression on the surface of primary macrophage binds both to HLA-A2 (Median percent$_{NT}$ =

1.09 vs Median percent$_{LILRB2}$ = 3.60 ; P=0.0078, Fig. 8e) and HLA-B27 (Median percent$_{NT}$ = 16.61 vs

Median percent$_{LILRB2}$ = 31.32 ; P=0.0273, Fig. 8f) suggesting that LILRB2 expression on the macrophages

surface can be part of the immunological synapse between recipient-derived pro-inflammatory *CXCL10*+

macrophages and donor cells.

A previous in vitro study has demonstrated that when LILRB2 is expressed on the surface of tolerogenic

dendritic cells, it generates an antiproliferative signal to autologous T cells[83]. Here, we tested whether

macrophages overexpressing LILRB2 would have an impact on the proliferation of autologous T cells

(Fig. 8g). Compared with activated T cells alone, the addition of M0 macrophages to the culture slightly

reduced cell proliferation, potentially through competition for nutrients (Fig. 8h). Interestingly, co-culture of

LILRB2-overexpressing macrophages with T cells did not decrease T cell proliferation at a 1$_{macro}$:1$_{T\ cell\ ratio}$.

Moreover, at a 1$_{macro}$:4$_{T\ cell\ ratio}$, T-cell proliferation increased significantly in the presence of macrophages

overexpressing LILRB2 (P=0.0273, Fig. 6I) suggesting that LILRB2 overexpression at macrophages

surface can generate a signal that positively impacts autologous T cell proliferation (Fig.9).

DISCUSSION

In the present study, we investigated circulating and allograft-infiltrating myeloid populations after

kidney transplantation. To this end, we gathered a substantial amount of scRNAseq data from several

study groups, several tissues (blood and biopsies) and several types of rejection in order to obtain a

generalizable characterization of recipient monocyte/macrophage infiltration into the graft. Among the

macrophage found within the allograft, we distinguished unsupervisedly two main populations, *CXCL10*+

macrophages and *SELENOP*+ macrophages. In addition to rejection-associated *CXCL10*+ macrophages,

we identified *SELENOP*+ macrophages as the main macrophagic subset populating the kidney allograft.

SELENOP+ macrophages show a very distinct transcriptomic profile as compare to *in vitro* differentiated

M2 macrophages confirming that the M1-M2 classification is irrelevant in the context of allotransplantation

and the description of macrophages *in vivo*. In line with our findings, Stewart and colleagues reported the

existence of a subset of *bona fide* resident macrophages they annotated "MNP-d" and expressing high

level of *SELENOP* (often also designated as *SEPP1*), *C1QC* and *RNASE1* in the native kidney[84]. In

addition, these *SELENOP*+ macrophages specifically express *CD81*, a marker for resident macrophages

that is conserved in mammalian species and more specifically in mouse, rat, pig and human kidney

tissue[85]. Intriguingly, among *SELENOP*+ macrophages, only recipient-derived macrophages resulting

from differentiation and infiltration of circulating monocytes expressed the trigger receptor expressed on

myeloid cells 2 (TREM2). TREM2 was first described in macrophage infiltrating adipose tissue[86], a

population derived from monocytes and named "lipid-associated macrophages, LAMs" because they

share a common gene expression program enriched in lipid metabolism-related genes, including *TREM2*,

APOE, and *GPNMB*[87]. Here, we showed that donor-derived macrophages expressed high levels of

SELENOP but not *TREM2* suggesting that TREM2 characterizes monocyte-derived macrophages that

repopulate the kidney allograft after transplantation whereas *SELENOPhi* macrophages could derive from

self-renewal of donor macrophages.

In contrast, *CXCL10*+ macrophages are uniquely derived from recipient monocytes and are major

contributors of allograft inflammation during rejection independent of other immune cells. Inparticular, this

population is absent in the allograft pre-transplantation and dramatically increases during rejection,

expressing massive levels of the proinflammatory chemokines *CXCL10* and *CXCL9*. Importantly, these

chemokines have been confirmed in a recent large-scale transcriptomic study as essential mediators of

rejection in all types of solid organ transplantation, regardless of the transplanted organ or the subtypes of

rejection[3]. Along with chemokine transcripts, *CXCL10*+ macrophages also strongly express *GBP1*, *GBP4*,

GBP5 and *WARS*, suggesting that these transcripts detected in bulk transcriptomic obtained from

allograft biopsy samples and forming genes signatures of rejection[62] originate primarily from this

macrophage population. Importantly, WARS and GBP1 were confirmed as enriched at protein level in the

allograft upon rejection[88,89]. *CXCL10*+ macrophages also specifically express *ANKRD22* encoding Ankyrin

repeat domain 22 (ANKRD22), a nuclear-encoded mitochondrial membrane protein that regulates

mitochondrial Ca2+ and the Wnt pathway. *Ankrd22*[-/-] mice showed reduced inflammation by inhibiting

macrophages tissue infiltration and TNF secretion after gastric mucosal injury[90]. It is noteworthy that

upregulation of ANKRD22 has previously been associated with macrophages activation in patients during

kidney transplant rejection[91].

At ontogenic level, *CXCL10*+ macrophages originate from recipient-derived circulating classical

monocytes. These differentiate into intermediate monocytes, then progress either to a non-classical

monocyte phenotype, as reported in the context of systemic infection[73], or to macrophage differentiation.

Importantly, we identified 6 core genes specifically associated with the *CXCL10*+ macrophages

differentiation: *FCN1*, *LY6E*, *LST1*, *LILRA2*, *LILRB2* and *LILRA5*. Among these 6 genes, the expression

of four of them, *FCN1*, *LST1*, *LILRA2* and *LILRB2*, is systematically increased in biopsies showing

rejection, as shown by our external validations using the PROMAD atlas.

FCN1 encodes Ficolin-1, a protein localized in the secretory granules of monocytes cytoplasm.

Mechanistically, Ficolin-1 forms active proteolytic complexes with MBL-associated serine proteases,

activating complement via the lectin pathway[92]. Importantly, C4b deposition increases with the amount of

Ficolin-1[93]. Whether *CXCL10*+ macrophages can induce complement activation via Ficolin-1 sensing

during kidney allograft rejection, independently of the humoral response remains to be investigated.

LY6E encodes a GPI-anchored cell surface protein called Lymphocyte antigen 6 complex locus

E, which is involved in cell-cell adhesion and immunological synapse[94]. Further investigations must be

pursued to determine the role of this protein in inflammatory macrophages infiltrating the graft.

LST1 is encoded within the Major Histocompatibility Complex class III region on the short arm of

chromosome 6, specifically including genes encoding components of the complement system such as

C2, C4 and cytokines such as TNF[95]. *LST1* is notably included in the B-HOT panel as one of the

transcripts most implicated in solid organ rejection[63]. It is highly polymorphic and its rs2256965 single

nucleotide polymorphism is associated with a susceptibility for nephritis in systemic lupus erythematous

patients[96].*LILRB2*, *LILRA2* and *LILRA5* encode LILRs which have been shown to be essential in the

allorecognition process of myeloid cells[64,72]. Like *LST1*, *LILRB2* is also included in the B-HOT panel [63].

Interestingly, cross-linking LILRA5 on the surface of monocyte induces the mobilization of calcium, a

known signaling mediator that is released during cell activation. In addition, triggering of LILRA5 on

monocytes induces the secretion of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and IL-6. IL-

1β, TNF-α, and IL-6 are normally released in the early stages of inflammatory responses, suggesting that

LILRA5 might play a role in modulating monocyte function in inflammatory settings[97].

While the ligand of LILRA5 and LILRA2 is still unknown[82], LILRB2 has been reported as a

putative binder for HLA class I[98], which was previously confirmed *in vitro* in transfected 293T cells and ex

vivo in CD14- myelomonocytic cells[99]. Here we showed that after CD47/SIRP-◻ activation, classical

monocytes overexpress LILRB2 on their surface together with CD16, suggesting that they initiate their

differentiation into intermediate-monocytes. Moreover, this increase of LILRB2 in classical monocytes was

also detected in the blood of patient with rejection one year after transplantation compared to patients

with no rejection. Whether this increase in LILRB2 in circulating monocyte might reflect some myeloid

immune memory towards nonself HLA in patients, as suggested in mice[72], remains to be validated in

larger cohorts in which SIRP-◻ mismatches can be monitored. Interestingly, a population of

proinflammatory macrophages strongly expressing LILRB2 has been reported to infiltrate the synovium of

patients with rheumatoid arthritis[100]. LILRB2 was historically described as inhibitory because it includes

ITIMs motifs at its intracellular part but it was recently reported that PirB/LILRB2 were expressed in

hepatic macrophages and bound with their NASH-associated ligand ANGPTL8 to trigger the recruitment

of macrophages to the liver, providing evidence that the LILRB2/PirB-ANGPTL8 axis could be a

pathogenic driver of NASH pathogenesis and fibrogenesis. Notably, an PirB/LILRB2-ANGPTL8

interaction facilitates the differentiation of hepatic macrophages to a proinflammatory phenotype by

enhancing the phosphorylation of P38, AKT, and P65 signals, which in turn causes an aggravation in

hepatocyte lipid accumulation and an exacerbation from simple hepatic steatosis to steatohepatitis. This

report also uncovers a function of PirB/LILRB2 receptors in monocytes migration which is in line with the

present study[101] showing a specific increase in LILRB2 expression in recipient monocytes/macrophages

infiltrating the allograft. Of note, ANGPTL8 is liver-specific and the LILRB2 ligand in kidney transplantation

context remains to be characterized. Here, we showed that LILRB2 overexpression at macrophage's

surface can bind class I HLA and does not induce any antiproliferative signal to autologous T cells,

suggesting that the increase of LILRB2 at *CXCL10*+ macrophages cell surface does not limit recipient T

cells response during rejection. Instead, our results suggest that LILRB2, expressed by monocytes and

then *CXCL10*+ macrophages, delivers an inflammatory signal to the myeloid cell in the allogeneic context.

Our study does not allow us to conclude that it is the binding of LILRB2 to non-self HLA that induces this

differentiation into *CXCL10*+ macrophages. For this, further investigations are required.

Our study has several limitations: we were unable to confirm the inflammatory

monocyte/macrophage trajectories in another external dataset, but this work could be conducted in the

coming years as the number of scRNASeq studies in human kidney transplantation increases every year.

Spatial transcriptomics analyses would also allow us to better characterize the profile of *CXCL10*+

macrophages. It should be noted, that very recently, a spatial transcriptomics approach was carried out

on FFPE-included renal graft biopsies, corroborating our findings. In this study, they confirm that

monocytes and macrophages expressing *FCGR3A* are central to graft rejection, whatever the subtype of

rejection. Using this new technique, they confirm that the *CXCL9*, *CXCL10*, *WARS*, *GBP1* and *GBP4*

transcripts, which are *CXCL10*+ macrophages-specific transcripts as we described here, are universal

transcripts associated with acute rejection. They also demonstrate upregulation of *CD47* and *SIRPA* in

both TCMR and AMR suggesting that this CD47/SIRP-α axis is relevant in our study in order to

investigate monocyte activation during allograft rejection[102].

In addition, we were unable to integrate scRNASeq data from the blood of patients with non-AMR

rejection and thus cannot conclude that blood monocytes behave in exactly the same way as in AMR or

stable patients with this type of rejection. Nevertheless, given that intragraft chemokine secretion

measurable in urine is increased in both AMR and TCMR, this may indicate that monocyte trajectories are

similar in both types of rejection. Furthermore, our in vivo flow cytometry study of LILRs expression in

patient's blood is monocentric and limited by its small size. Moreover, it includes only a single post-

transplant time point and does not allow us to speculate on the modulation of monocyte LILRB2 in the

longer term. Larger-scale confirmations at several post-transplant timings are needed to demonstrate

increased LILRB2 expression in classical monocytes, which may reflect allogeneic activation. Finally, our

in vitro analyses on the impact of LILRB2 in inflammatory macrophages remains limited by the use of

differentiation by LPS and IFN-γ which, as we have shown, does not 100% reflect the profile of *CXCL10*+

macrophages found within the graft. Of note, several teams have proposed and developed strategies to

target monocytes and macrophages as a whole, with promising and encouraging results in the context of

kidney transplantation [103–105]. The present study provides further insight into the pro-inflammatory axes of

recipient-derived monocytes/macrophages, and suggests LILRB2 as a therapeutic target.

Acknowledgments:

We thank the clinicians and surgeons, nursing staff and the patients of Dijon University Hospital. We

thank Mickaël Ménager (Imagine Insitute, Paris) for providing the Vpx lentiviral vector. We thank Babacar

Ndao (Inserm UMR Right, Besançon, France) for his help with fastq alignements. We thank Emilie Gaiffe,

Caroline Laheurte and Eleonore Gravelin (Inserm UMR Right, Besançon, France) for their help with

ORLY-EST samples. We thank Dr Christophe Masset (KU Leuven, Belgium) for providing the survival

data associated with GSE147089. Figures 1a, 3a, 4a, 6a, 7a, 8a, 8g and 9 were created using Biorender.

Data sharing statement:

All omic data are already publicly available. All data produced in the present study are available upon

reasonable request to the authors. The complete codebase developed for the unsupervised differentiation

trajectory analysis of myeloid cells is publicly available as a Jupyter Notebook at

https://github.com/InsermRightLab/LILRB2-Varin-et-al/. It provides a detailed, step-by-step walkthrough of

the computational workflow used to generate each figure, encompassing pseudotime inference using

slingshot and identification of differentially expressed genes via tradeSeq. The primary functions,

especially those integral to the computational workflow, have been consolidated into RightOmicsTools, an

R package available at https://alexis-varin.github.io/RightOmicsTools/. Additional supporting code,

including utility functions, is provided within the notebook repository to ensure transparency and

reproducibility. Code for Seurat is available at https://satijalab.org/seurat/. Code for CellChat is available

at https://github.com/jinworks/CellChat/. Code for slingshot is available at

https://github.com/kstreet13/slingshot/. Code for tradeSeq is available at

https://github.com/statOmics/tradeSeq/.

References

1. Callemeyn, J. *et al.* Allorecognition and the spectrum of kidney transplant rejection. *Kidney Int* (2021) doi:10.1016/j.kint.2021.11.029.

2. Calvani, J. *et al.* In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response. *American Journal of Transplantation* **20**, 942–953 (2020).

3. Robertson, H. *et al.* Decoding the hallmarks of allograft dysfunction with a comprehensive pan-organ transcriptomic atlas. *Nat Med* (2024) doi:10.1038/s41591-024-03030-6.

4. Vaulet, T. & Naesens, M. Stronger together: the power of cross-organ data sets for improved allograft study outcomes. *Kidney Int* **106**, 783–786 (2024).

5. Park, S. *et al.* European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection. *Transplant International* **36**, (2024).

6. Van Loon, E. *et al.* Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study. *Am J Kidney Dis* **83**, 467–476 (2024).

7. Tinel, C. *et al.* Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. *American Journal of Transplantation* **20**, 3462–3476 (2020).

8. Rabant, M. *et al.* Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibody-mediated kidney allograft rejection. *Journal of the American Society of Nephrology* **26**, 2840–2851 (2015).

9. Tinel, C. *et al.* Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation. *Sci Rep* **14**, 20357 (2024).

10. Abou-Daya, K. I. & Oberbarnscheidt, M. H. Innate allorecognition in transplantation. *J Heart Lung Transplant* **40**, 557–561 (2021).

11. Oberbarnscheidt, M. H. *et al.* Non-self recognition by monocytes initiates allograft rejection. *Journal of Clinical Investigation* **124**, 3579–3589 (2014).

12. Fox, A., Mountford, J., Braakhuis, A. & Harrison, L. C. Innate and Adaptive Immune Responses to Nonvascular Xenografts: Evidence That Macrophages Are Direct Effectors of Xenograft Rejection. *The Journal of Immunology* **166**, 2133–2140 (2001).

13. Liu, W., Xiao, X., Demirci, G., Madsen, J. & Li, X. C. Innate NK Cells and Macrophages Recognize and Reject Allogeneic Nonself In Vivo via Different Mechanisms. *The Journal of Immunology* **188**, 2703–2711 (2012).

14. Malone, A. F. *et al.* Harnessing Expressed Single Nucleotide Variation and Single Cell RNA Sequencing to Define Immune Cell Chimerism in the Rejecting Kidney Transplant. *Journal of the American Society of Nephrology* **31**, 1977–1986 (2020).

15. Cormican, S. *et al.* Chronic Kidney Disease Is Characterized by Expansion of a Distinct Proinflammatory Intermediate Monocyte Subtype and by Increased Monocyte Adhesion to Endothelial Cells. *Journal of the American Society of Nephrology* **34**, 793–808 (2023).

16. Menon, R. *et al.* Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. *JCI Insight* **5**, (2020).

17. Van Loon, E. *et al.* Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. *Kidney Int* **102**, 183–195 (2022).

18. Lamarthée, B. *et al.* Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcγRIII+ innate immune cells in rejection. *Nat Commun* **14**, (2023).

19. Shi, T. *et al.* Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality. *Journal of Clinical Investigation* **133**, (2023).

20. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *bioRxiv* 2020.10.12.335331 (2020) doi:10.1101/2020.10.12.335331.

21. Stewart, B. J. *et al.* Spatio-temporal immune zonation of the human kidney Europe PMC Funders Group. **365**, 1461–1466 (2019).

22. Lake, B. B. *et al.* An atlas of healthy and injured cell states and niches in the human kidney. *Nature* **619**, 585–594 (2023).

23. Wigerblad, G. *et al.* Single-Cell Analysis Reveals the Range of Transcriptional States of Circulating Human Neutrophils. *The Journal of Immunology* **209**, 772–782 (2022).

24. Shankland, S. J., Smeets, B., Pippin, J. W. & Moeller, M. J. The emergence of the glomerular
parietal epithelial cell. *Nature Reviews Nephrology* vol. 10 158–173 Preprint at
https://doi.org/10.1038/nrneph.2014.1 (2014).
25. Tran, T. *et al.* In Vivo Developmental Trajectories of Human Podocyte Inform In Vitro
Differentiation of Pluripotent Stem Cell-Derived Podocytes. *Dev Cell* **50**, 102-116.e6 (2019).
26. Schumacher, A. *et al.* Defining the variety of cell types in developing and adult human kidneys by
single-cell RNA sequencing. *npj Regenerative Medicine* vol. 6 Preprint at
https://doi.org/10.1038/s41536-021-00156-w (2021).
27. Varin, A. RightOmicsTools: An R Package Providing Complementary Tools for the Manipulation
and Visualization of Single Cell RNA-Seq Data. Preprint at
https://doi.org/10.5281/zenodo.12518909 (2025).
28. Thomas, G., Tacke, R., Hedrick, C. C. & Hanna, R. N. Nonclassical Patrolling Monocyte Function
in the Vasculature. *Arterioscler Thromb Vasc Biol* **35**, 1306–1316 (2015).
29. Li, Z. *et al.* CD83: Activation marker for antigen presenting cells and its therapeutic potential.
Frontiers in Immunology vol. 10 Preprint at https://doi.org/10.3389/fimmu.2019.01312 (2019).
30. Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring.
Comput Struct Biotechnol J **19**, 3796–3798 (2021).
31. Jin, S., Plikus, M. V & Nie, Q. CellChat for systematic analysis of cell-cell communication from
single-cell and spatially resolved transcriptomics. *bioRxiv* 2023.11.05.565674 (2023)
doi:10.1101/2023.11.05.565674.
32. van der Touw, W., Chen, H. M., Pan, P. Y. & Chen, S. H. LILRB receptor-mediated regulation of
myeloid cell maturation and function. *Cancer Immunology, Immunotherapy* vol. 66 1079–1087
Preprint at https://doi.org/10.1007/s00262-017-2023-x (2017).
33. Redondo-García, S. *et al.* Human leukocyte immunoglobulin-like receptors in health and disease.
Frontiers in Immunology vol. 14 Preprint at https://doi.org/10.3389/fimmu.2023.1282874 (2023).
34. Lakkis, F. G. & Li, X. C. Innate allorecognition by monocytic cells and its role in graft rejection.
American Journal of Transplantation vol. 18 289–292 Preprint at https://doi.org/10.1111/ajt.14436
(2018).
35. Ennis, S., Ó Broin, P. & Szegezdi, E. CCPlotR: an R package for the visualization of cell–cell
interactions. *Bioinformatics Advances* **3**, vbad130 (2023).
36. Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics.
BMC Genomics **19**, 477 (2018).
37. Van den Berge, K. *et al.* Trajectory-based differential expression analysis for single-cell sequencing
data. *Nat Commun* **11**, (2020).
38. Badia-I-Mompel, P. *et al.* decoupleR: ensemble of computational methods to infer biological
activities from omics data. *Bioinformatics Advances* **2**, (2022).
39. Müller-Dott, S. *et al.* Expanding the coverage of regulons from high-confidence prior knowledge for
accurate estimation of transcription factor activities. *Nucleic Acids Res* **51**, 10934–10949 (2023).
40. Newman, A. M. *et al.* Determining cell type abundance and expression from bulk tissues with
digital cytometry. *Nat Biotechnol* **37**, 773–782 (2019).
41. Hu, M. & Chikina, M. Heterogeneous pseudobulk simulation enables realistic benchmarking of cell-
type deconvolution methods. *Genome Biol* **25**, (2024).
42. Einecke, G. *et al.* A molecular classifier for predicting future graft loss in late kidney transplant
biopsies. *Journal of Clinical Investigation* **120**, 1862–1872 (2010).
43. Reeve, J. *et al.* Molecular diagnosis of T cell-mediated rejection in human kidney transplant
biopsies. *American Journal of Transplantation* **13**, 645–655 (2013).
44. Halloran, P. F. *et al.* Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-
Mediated Rejection in Late Kidney Transplant Recipients. *Journal of the American Society of
Nephrology* **26**, (2015).
45. Reeve, J. *et al.* Assessing rejection-related disease in kidney transplant biopsies based on archetypal
analysis of molecular phenotypes. *JCI Insight* **2**, (2017).
46. Callemeyn, J. *et al.* Transcriptional Changes in Kidney Allografts with Histology of Antibody-
Mediated Rejection without Anti-HLA Donor-Specific Antibodies. *Journal of the American Society
of Nephrology* **31**, (2020).
47. Archer, K. J. *et al.* Pretransplant kidney transcriptome captures intrinsic donor organ quality and
predicts 24-month outcomes. *American Journal of Transplantation* **22**, 2515–2528 (2022).

48. Taverna, F. *et al.* BIOMEX: an interactive workflow for (single cell) omics data interpretation and
943   visualization. *Nucleic Acids Res* **48**, W385–W394 (2020).
944   49. Gurvich, O. L. *et al.* Transcriptomics uncovers substantial variability associated with alterations in
945   manufacturing processes of macrophage cell therapy products. *Sci Rep* **10**, 14049 (2020).
946   50. Manel, N. *et al.* A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells.
947   *Nature* **467**, 214–217 (2010).
948   51. Tinel, C. *et al.* Modulation of Monocyte Response by MicroRNA-15b/106a/374a During Antibody-
949   mediated Rejection in Kidney Transplantation. *Transplantation* **107**, 1089–1101 (2023).
950   52. Van Gassen, S., Gaudilliere, B., Angst, M. S., Saeys, Y. & Aghaeepour, N. CytoNorm: A
951   Normalization Algorithm for Cytometry Data. *Cytometry Part A* **97**, 268–278 (2020).
952   53. Fletez-Brant, K., Špidlen, J., Brinkman, R. R., Roederer, M. & Chattopadhyay, P. K. flowClean:
953   Automated identification and removal of fluorescence anomalies in flow cytometry data. *Cytometry*
954   *Part A* **89**, 461–471 (2016).
955   54. Vaulet, T. *et al.* Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney
956   Transplant Rejection using Semi-supervised Clustering. *Journal of the American Society of*
957   *Nephrology* **32**, 1084–1096 (2021).
958   55. Naesens, M., Cornell, L. D., Seshan, S. V. & Haas, M. Toward Activity and Chronicity Indices for
959   the Evaluation of Kidney Transplant Rejection: A Viewpoint by the Banff Working Group.
960   *Transplantation* (2025) doi:10.1097/TP.0000000000005336.
961   56. Heagerty, P. J., Lumley, T. & Pepe2, M. S. *Time-Dependent ROC Curves for Censored Survival*
962   *Data and a Diagnostic Marker.* (2000).
963   57. Youden, W. J. Index for rating diagnostic tests. *Cancer* **3**, 32–35 (1950).
964   58. Kaplan, E. L. & Meier, P. *Nonparametric Estimation from Incomplete Observations. Source:*
965   *Journal of the American Statistical Association* vol. 53 (1958).
966   59. Therneau, T. M. & Grambsch, P. M. *Modeling Survival Data: Extending the Cox Model.* (2000).
967   60. Kassambara, A., Kosinski, M. & Biecek, P. survminer: Drawing Survival Curves using 'ggplot2'.
968   Preprint at https://rpkgs.datanovia.com/survminer/index.html (2024).
969   61. Bräsen, J. H. *et al.* Macrophage density in early surveillance biopsies predicts future renal transplant
970   function. *Kidney Int* **92**, 479–489 (2017).
971   62. Halloran, P. F. *et al.* Review: The transcripts associated with organ allograft rejection. *American*
972   *Journal of Transplantation* vol. 18 785–795 Preprint at https://doi.org/10.1111/ajt.14600 (2018).
973   63. Mengel, M. *et al.* Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–
974   Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter
975   validation. *American Journal of Transplantation* **20**, 2305–2317 (2020).
976   64. Palvair, J. *et al.* The Potential Role of the Leucocyte Immunoglobulin-Like Receptors in Kidney
977   Transplant Rejection: A Mini Review. *Transplant International* **37**, (2024).
978   65. Edwards, P. A., Kast, H. R. & Anisfeld, A. M. BAREing it all: the adoption of LXR and FXR and
979   their roles in lipid homeostasis. *J Lipid Res* **43**, 2–12 (2002).
980   66. Jessica, B. *et al.* Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF-κB and
981   Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. *J Virol* **88**, 1582–1590 (2014).
982   67. Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. Identification of interferon-gamma as
983   the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J*
984   *Exp Med* **158**, 670–689 (1983).
985   68. Stein, M., Keshav, S., Harris, N. & Gordon, S. Interleukin 4 potently enhances murine macrophage
986   mannose receptor activity: a marker of alternative immunologic macrophage activation. *J Exp Med*
987   **176**, 287–292 (1992).
988   69. Pizzurro, G. A. & Miller-Jensen, K. Reframing macrophage diversity with network motifs. *Trends*
989   *Immunol* **44**, 965–970 (2023).
990   70. Lamarthée, B. *et al.* Transcriptional and spatial profiling of the kidney allograft unravels a central
991   role for FcγRIII+ innate immune cells in rejection. *Nat Commun* **14**, 4359 (2023).
992   71. Dai, H. *et al.* Donor SIRPα polymorphism modulates the innate immune response to allogeneic
993   grafts. *Sci Immunol* **2**, eaam6202 (2017).
994   72. Dai, H. *et al.* PIRs mediate innate myeloid cell memory to nonself MHC molecules. *Science (1979)*
995   **368**, 1122–1127 (2020).
996   73. Patel, A. A. *et al.* The fate and lifespan of human monocyte subsets in steady state and systemic
997   inflammation. *Journal of Experimental Medicine* **214**, 1913–1923 (2017).

74.   Bamoulid, J. *et al.* Pretransplant thymic function predicts acute rejection in antithymocyte globulin–
treated renal transplant recipients. *Kidney Int* **89**, 1136–1143 (2016).
75.   Riddell, S. R. & Greenberg, P. D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to
clone and expand human antigen-specific T cells. *J Immunol Methods* **128**, 189–201 (1990).
76.   Kajiho, Y. *et al.* SIRP **α** interacts with nephrin at the podocyte slit diaphragm. *FEBS J* **279**, 3010–
3021 (2012).
77.   Takahashi, S. *et al.* SIRPα signaling regulates podocyte structure and function. *American Journal of*
Physiology-Renal Physiology **305**, F861–F870 (2013).
78.   Kurihara, H., Harita, Y., Ichimura, K., Hattori, S. & Sakai, T. SIRP-α-CD47 system functions as an
intercellular signal in the renal glomerulus. *American Journal of Physiology-Renal Physiology* **299**,
F517–F527 (2010).
79.   Tsuchiya, S. *et al.* Establishment and characterization of a human acute monocytic leukemia cell
line (THP□1). *Int J Cancer* **26**, 171–176 (1980).
80.   Lu, H. K. *et al.* Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-
mediated monocyte activation via dephosphorylation of multiple kinases. *J Biol Chem* **284**, 34839–
48 (2009).
81.   Redondo-García, S. *et al.* Human leukocyte immunoglobulin-like receptors in health and disease.
Front Immunol **14**, (2023).
82.   van der Touw, W., Chen, H.-M., Pan, P.-Y. & Chen, S.-H. LILRB receptor-mediated regulation of
myeloid cell maturation and function. *Cancer Immunology, Immunotherapy* **66**, 1079–1087 (2017).
83.   Beinhauer, B. G. *et al.* Interleukin 10 regulates cell surface and soluble LIR□2 (CD85d) expression
on dendritic cells resulting in T cell hyporesponsiveness *in vitro*. *Eur J Immunol* **34**, 74–80 (2004).
84.   Stewart, B. J. *et al.* Spatiotemporal immune zonation of the human kidney. *Science (1979)* **365**,
1461–1466 (2019).
85.   Zimmerman, K. A. *et al.* Single-Cell RNA Sequencing Identifies Candidate Renal Resident
Macrophage Gene Expression Signatures across Species. *Journal of the American Society of*
Nephrology **30**, 767–781 (2019).
86.   Jaitin, D. A. *et al.* Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-
Dependent Manner. *Cell* **178**, 686-698.e14 (2019).
87.   Behmoaras, J., Mulder, K., Ginhoux, F. & Petretto, E. The spatial and temporal activation of
macrophages during fibrosis. *Nat Rev Immunol* (2025) doi:10.1038/s41577-025-01186-x.
88.   Chauveau, B. *et al.* WARS1, TYMP and GBP1 display a distinctive microcirculation pattern by
immunohistochemistry during antibody-mediated rejection in kidney transplantation. *Sci Rep* **12**,
(2022).
89.   Chauveau, B. *et al.* The Proteome of Antibody-Mediated Rejection: From Glomerulitis to
Transplant Glomerulopathy. *Biomedicines* **10**, 569 (2022).
90.   Liu, J. *et al.* ANKRD22 Drives Rapid Proliferation of Lgr5+ Cells and Acts as a Promising
Therapeutic Target in Gastric Mucosal Injury. *Cell Mol Gastroenterol Hepatol* **12**, 1433–1455
(2021).
91.   Venner, J. M. *et al.* Molecular Landscape of T Cell–Mediated Rejection in Human Kidney
Transplants: Prominence of CTLA4 and PD Ligands. *American Journal of Transplantation* **14**,
2565–2576 (2014).
92.   Garred, P., Honoré, C., Ma, Y. J., Munthe-Fog, L. & Hummelshøj, T. MBL2, FCN1, FCN2 and
FCN3—The genes behind the initiation of the lectin pathway of complement. *Mol Immunol* **46**,
2737–2744 (2009).
93.   Liu, Y. *et al.* Human M-Ficolin Is a Secretory Protein That Activates the Lectin Complement
Pathway. *The Journal of Immunology* **175**, 3150–3156 (2005).
94.   Classon, B. J. & Boyd, R. L. Thymic□Shared Antigen□1 (TSA□1) A Lymphostromal Cell
Membrane Ly□6 Superfamily Molecule with a Putative Role in Cellular Adhesion. *J Immunol Res*
6, 149–156 (1998).
95.   Rollinger-Holzinger, I. *et al.* LST1□: A Gene with Extensive Alternative Splicing and
Immunomodulatory Function. *The Journal of Immunology* **164**, 3169–3176 (2000).
96.   Mewar, D. *et al.* Haplotype-specific gene expression profiles in a telomeric major histocompatibility
complex gene cluster and susceptibility to autoimmune diseases. *Genes Immun* **7**, 625–631 (2006).
97.   Borges, L., Kubin, M. & Kuhlman, T. LIR9, an immunoglobulin-superfamily–activating receptor, is
expressed as a transmembrane and as a secreted molecule. *Blood* **101**, 1484–1486 (2003).

98. Shiroishi, M. *et al.* Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with
CD8 for MHC class I binding and bind preferentially to HLA-G. *Proceedings of the National*
Academy of Sciences **100**, 8856–8861 (2003).
99. Allen, R. L., Raine, T., Haude, A., Trowsdale, J. & Wilson, M. J. Cutting Edge: Leukocyte Receptor
Complex-Encoded Immunomodulatory Receptors Show Differing Specificity for Alternative HLA-
B27 Structures. *The Journal of Immunology* **167**, 5543–5547 (2001).
100. Tedla, N. *et al.* The Co-Expression of Activating and Inhibitory Leukocyte Immunoglobulin-Like
Receptors in Rheumatoid Synovium. *Am J Pathol* **160**, 425–431 (2002).
101. Li, D.-P. *et al.* LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic
steatohepatitis. *Nat Commun* **14**, 4436 (2023).
102. Wongworawat, Y. C. *et al.* Spatial Transcriptomics Using Archived Formalin-Fixed Paraffin-
Embedded Core Needle Biopsy Tissues Revealed Unique Transcriptomic Signatures in Kidney
Transplant Rejections. *bioRxiv* 2025.04.08.647600 (2025) doi:10.1101/2025.04.08.647600.
103. Kitchens, W. H. *et al.* Macrophage depletion suppresses cardiac allograft vasculopathy in mice. *Am*
J Transplant **7**, 2675–2682 (2007).
104. Jose, M. D., Ikezumi, Y., van Rooijen, N., Atkins, R. C. & Chadban, S. J. Macrophages act as
effectors of tissue damage in acute renal allograft rejection. *Transplantation* **76**, 1015–1022 (2003).
105. Lai, C. *et al.* Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute
kidney allograft rejection. *Kidney Int* **102**, 1090–1102 (2022).

1073

1074

1075 **Figures Legend**

Fig. 1. **Single-cell integration of kidney allograft and blood-derived cells.** a. Experimental Approach. 46 scRNAseq datasets from kidney transplant patients were used for this analysis (n⌐=⌐13 blood with 5 no rejection and 8 rejection, and n = 33 kidney allograft biopsies with 13 no rejection and 20 rejection). b. Polar plot of the 28 rejection samples showing tissue origin and estimated inflammation level severity. c. Clustered dot plot showing average gene expression values of canonical markers (log normalized) and expression percentage of cell types represented on the Uniform Manifold Approximation and Projection (UMAP) plot. d. UMAP plot of 150,876 cells passing QC filtering and doublets removal. The main kidney cell types are represented, including loop of Henle (LOH), podocytes, vascular smooth muscle and pericytes (vSMp), proximal tubule (PT), intercalated cells type A and B (IC_A / IC_B), three endothelial cell subsets comprising vasa recta (ECvr), glomerular (ECg) and peritubular capillaries (ECptc), myeloid cells, lymphoid cells, megakaryocytes, and proliferating cells. e. Stacked barplots representing the relative cell proportion of each cell type on the UMAP plot, split by tissue origin (blood or kidney allograft biopsies) and by outcome (no rejection or rejection). f. Word cloud obtained using the computeEnrichmentScore function of Seurat and split by outcome (no rejection or rejection).

Fig. 2. A proinflammatory macrophage subpopulation expressing *CXCL10* is specifically enriched during rejection. a. UMAP plot of 37,847 cells following Seurat's reintegration of monocytes, macrophages and cDC cell types from the main object. The main myeloid cell types are represented, including the three expected subsets of monocytes (Classical-mo, Intermediate-mo and Non-classical-mo) as well as more specific subtypes such as classical monocytes activated by interferon-gamma (IFN-activated-mo), classical monocytes in the process of differentiating into monocyte-derived dendritic cells (Mo-DC), and non-classical monocytes expressing higher levels of adhesion molecules (Patrolling-mo). Three subtypes of dendritic cells were also found, with both expected main conventional subsets (cDC1 and cDC2) and a *CD14+ CD83+* cluster of monocyte-derived mature dendritic cells (*CD83+* mature DC). Finally, two macrophages' subtypes were identified, one expressing high levels of *SELENOP* (*SELENOP+⌐*) and another expressing high levels of several chemokines (*CXCL10+⌐*). b. Clustered dot plot showing average gene expression values of canonical markers (log normalized) and expression percentage of major cell types represented on the UMAP plot. c. Stacked barplots representing the relative cell proportion of each myeloid cell type among all kidney allograft cells, split by outcome (no rejection or rejection). d. Scatterplot representing the relative proportion ratio of each myeloid cell type among all kidney allograft cells in no rejection versus rejection samples, defining an infiltration score for each myeloid cell type during rejection. e. Barplots showing the relative proportion of *SELENOP+* and *CXCL10+* macrophages among all myeloid cells in no rejection versus rejection samples. Two-tailed Mann–Whitney tests comparing No rejection and Rejection samples indicate significant difference in *CXCL10+* macrophages proportions but not in *SELENOP+* macrophages proportions. Two-tailed Mann Whitney tests were performed to compare the groups. P-values are shown. f. Volcano plot representing DEG between *SELENOP+* and *CXCL10+* macrophages. g. Heatmap representing the transcription factor activity regulating the DEG between *SELENOP+* and *CXCL10+* macrophages.

Fig. 3. *CXCL10+* macrophages are absent pre-transplantation and dramatically increase upon acute rejection. a. Experimental approach. scRNAseq-derived signature matrix was used for deconvolution of the dataset GSE147451 encompassing 192 transcriptomes from pre-transplant kidney biopsies, the dataset GSE98320 encompassing 489 transcriptomes from post-transplant biopsies with rejection phenotypes and Banff lesions scores as well as the datasets GSE48581 and GSE36059 encompassing 189 transcriptomes from post-transplant biopsies with rejection phenotypes. b. Frequency of *CXCL10+* macrophages within the allograft inferred by deconvolution in GSE147451, GSE98320, GSE48581 and GSE36059 and stratified according to clinical outcome. No MOA = No Major Abnormality, IFTA = Interstitial Fibrosis and Tubular Atrophy, AMR = Antibody-Mediated Rejection, TCMR = T Cell-Mediated Rejection. The difference between groups was assessed by a two-tailed Kruskal-Wallis test and multiple comparisons using the Dunn's test. P-values are shown. c. Pearson's correlation coefficient and -log10 of the associated p-value, represented by a dot, with the 95% confidence interval indicated by error bars, for the correlation between the sum of Banff lesion scores related to acute rejection and the frequency of different immune cells within the allograft inferred by deconvolution in GSE98320. d. Frequency of *CXCL10+* macrophages within the allograft inferred by deconvolution in GSE98320 and stratified according to Banff lesion scores of acute rejection. The difference between groups was assessed by a two-tailed Kruskal-Wallis test and multiple comparisons using the Dunn's test. P-values are shown.

Fig. 4. *CXCL10+* macrophages infiltration is associated with graft loss, independent of other immune cells. a. Experimental approach. scRNAseq-derived signature matrix was used for deconvolution of the datasets GSE147089 and GSE21374 encompassing 504 transcriptomes from post-transplant biopsies with survival metadata. b. After evaluating the diagnostic accuracy of *CXCL10+* macrophages infiltration for predicting graft loss using time-dependent ROC curve analysis at one-year post biopsy, the optimal cutoff of the *CXCL10+* macrophages proportion that maximizes the Youden index was calculated from the sensitivity and specificity values of the model (J_{max}=0.984%). c. Kaplan Meier curves of allograft survival data right-censored at five-years post biopsy based on *CXCL10+* macrophages proportion, stratified in two groups using the calculated Youden index cutoff at one-year post biopsy. The difference in survival between the two groups was assessed using the log-rank test. P-value is shown. d-e Univariate and multivariate Cox proportional hazards analysis of allograft survival data right-censored at one-year post biopsy, with the proportion of the four cell types most-associated with the activity index inflammation within the allograft as predictors, stratified in two groups using their respective calculated Youden index cutoffs at one-year post biopsy. P-values are shown.

Fig. 5. Myeloid cells differentiation is driven by six main trajectories in kidney transplant recipients. a. UMAP plots of reintegrated myeloid cells showing the 6 unsupervised trajectories obtained from slingshot and represented on cell type annotations and tissue origin, as well as pseudotime values corresponding to these trajectories and knots determined by tradeSeq and segmenting each lineage. b. Scatterplots representing early DE test between knot 3 and 4 computed statistics (Wald statistic, mean log fold change and rank score for each gene) of fitted GAM expression smoothers in 5 within-lineage comparisons (CD83+ DC trajectory versus *CXCL10+⌐* trajectory, cDC1 trajectory versus *CXCL10+⌐* trajectory, *SELENOP+⌐* trajectory versus CXCL10+⌐ trajectory, Non-classical trajectory versus *CXCL10+⌐* trajectory and Patrolling trajectory versus CXCL10+⌐ trajectory). c. Venn diagram showing overlapping genes among the top 90th percentile rank score in each of the 5 within-lineage comparisons of the *CXCL10+* macrophages trajectory versus each other trajectory. d. Heatmap of the fitted GAM expression smoothers of 22 genes found to be significantly enriched in all 5 within-lineage comparisons of the *CXCL10+* macrophages trajectory versus each other trajectory, shown alongside the pseudotime of the *CXCL10+* macrophages lineage. Density of each cell type contributing to the trajectory is shown. e. Scatterplots of the log normalized expression and the corresponding fitted GAM expression smoothers curves of 6 significantly enriched genes in all 5 within-lineage comparisons of the *CXCL10+* macrophages trajectory versus each other trajectory, represented alongside the pseudotime of all 6 identified lineages.

1076

Fig. 6. LILRA2, LILRB1 and LILRB2 expression increases significantly in classical monocytes from patients with rejection. a. Eighty-four patients were included in the ORLY EST multicenter cohort. PBMC and serum were collected at D0 and D365 post-transplant and stored at the CRB and the histocompatibility laboratory of Dijon University Hospital respectively. The proposed study is an ancillary study based on flow cytometric analysis of LILR expression in leukocytes. b. Normalized Expression of indicated markers at indicated times in indicated monocyte population. Multiple paired t tests were performed using Holm-Šídák method to compare the groups. P-values are shown.

Fig. 7. Allogeneic activation of classical monocytes leads to increased expression of LILRB2. a. Schematic diagram of the experiments. b. Representative overlays histograms representing the expression of annotated markers in different stimulatory conditions. c. Geometric Mean MFI of each biological replicate (N=10). Wilcoxon matched-pairs signed rank tests were used and P-values are shown.

Fig. 8. Macrophages overexpressing LILRB2 bind HLA class I molecules, triggering their activation. a. Schematic diagram of the lentiviral strategy used here. b. Gating strategy showing the efficacy of the approach. c. Percent of LILRB2 hi macrophages after transduction. Two-tailed Mann Whitney test was performed to compare the groups. P-values is shown. d.Gating strategy for HLA binding assays. e-f. Percentages of HLA-A2 or B-27 cells. Two-tailed Mann Whitney tests were performed to compare the groups. P-values are shown. g. Schematic diagram of CD3-CD28 activated autologous T cell proliferation assay upon co-culture with LILRB2 hi macrophages. h-i. Division index of the activated T cell post co culture with LILRB2 hi macrophages. Wilcoxon matched-pairs signed rank tests were performed to compare the NT and LILRB2hi conditions. P-values are shown.

Fig. 9. Mechanism of activation of kidney transplant recipient-derived monocytes in the context of kidney transplantation. The upper part of the figure suggests that in a context of balanced signals provided by CD47 and SIRPa, recipient-derived monocytes transform into *SELENOP*+ resident macrophages. In contrast, in the presence of an imbalanced CD47/SIRPA situation, monocytes transform into inflammatory macrophages expressing LILRB2 and CXCL10 or into memory monocytes overexpressing LILRB2.

Fig.1

Fig.2

Fig.3

Fig.4

Fig.6

a.

Blood from healthy volunteers → PBMC isolation → Classical-mo magnetic sorting → *In vitro* activation → Flow cytometry analysis

Monocytes

CD47

48h

b.

Type of activation
- Ig control
- anti-CD47

c.

LILRA2

P=0.1934

Geo Mean MFI

LILRA5

P=0.0137

LILRB1

P=0.0059

LILRB2

P=0.0273

CD16

P=0.0371

Type of activation
- Ig control
- anti-CD47

Fig.8